139 related articles for article (PubMed ID: 20519814)
1. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
Joshita S; Yoshizawa K; Sano K; Kobayashi S; Sekiguchi T; Morita S; Kamijo A; Komatsu M; Umemura T; Ichijo T; Matsumoto A; Tanaka E
Intern Med; 2010; 49(11):991-4. PubMed ID: 20519814
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
Huang WS; Yang CH
World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
[TBL] [Abstract][Full Text] [Related]
3. All that glitters: sorafenib.
Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
Intern Med; 2011; 50(7):797. PubMed ID: 21467725
[No Abstract] [Full Text] [Related]
4. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
Shiozawa K; Watanabe M; Takenaka H; Nagai H; Ishii K; Sakai K; Sumino Y
Hepatogastroenterology; 2010; 57(101):688-90. PubMed ID: 21033210
[TBL] [Abstract][Full Text] [Related]
5. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
Dogan E; Aksoy S; Arslan C; Dede DS; Altundag K
Med Oncol; 2010 Dec; 27(4):1436-7. PubMed ID: 20012235
[No Abstract] [Full Text] [Related]
6. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
7. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
[TBL] [Abstract][Full Text] [Related]
9. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
10. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
[No Abstract] [Full Text] [Related]
11. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
[TBL] [Abstract][Full Text] [Related]
12. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
[No Abstract] [Full Text] [Related]
13. [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
Shiozawa K; Watanabe M; Hirano N; Wakui N; Kikuchi Y; Hara F; Ishii K; Iida K; Sumino Y
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1713-5. PubMed ID: 21996974
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib for advanced hepatocellular carcinoma: a systematic review.
Ling-lin Z; Li M; Jin-hui T; Ke-hu Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):51-7. PubMed ID: 21375938
[TBL] [Abstract][Full Text] [Related]
15. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
16. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Kim SO; Han SY; Baek YH; Lee SW; Han JS; Kim BG; Cho JH; Nam KJ
World J Gastroenterol; 2011 Jan; 17(2):267-70. PubMed ID: 21246003
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib: in hepatocellular carcinoma.
Simpson D; Keating GM
Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
20. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
